Switch from abiraterone + prednisone to abiraterone + dexamethasone after PSA progression under abiraterone + prednisone in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients
Fenioux, C., Louvet, C., Prapotnich, D., Ropert, S., Barret, E., Sanchez-Salas, R., Mombet, A., Cathala, N., Poullennec, B., Joulia, M.-L., Ung, M., Cathelineau, X., Bennamoun, M.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article